Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2024-05-15 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券申请文件的第二轮审核问询函回复报告（2023年年度财务数据更新版）
Capital/Financing Update Classification · 95% confidence The document is a detailed response report to a second-round review inquiry letter from the Shanghai Stock Exchange regarding the company's application for issuing convertible bonds to unspecified investors. It includes extensive disclosures about the use of proceeds, project details, technical and human resources, market analysis, and risk assessments related to the fundraising projects. The document is signed by company and sponsor representatives, indicating it is a formal regulatory submission related to capital raising activities. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. Instead, it is clearly an update and response related to a capital raising process, specifically the issuance of convertible bonds. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2024-05-15 Chinese
关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券上市审核委员会会议意见落实函回复报告（2023年年度财务数据更新版）
Capital/Financing Update Classification · 95% confidence The document is a detailed response report from a company (奥锐特药业股份有限公司) and its sponsor (海通证券股份有限公司) addressing the Shanghai Stock Exchange's review committee's opinions regarding the company's issuance of convertible bonds to unspecified investors. The content includes extensive discussion on the feasibility and market prospects of a new production capacity project, detailed sales and production data, market analysis, and risk assessments. It also contains formal statements and legal responsibility declarations by the company's chairman and the sponsor's legal representatives. The document is about addressing regulatory review comments and providing detailed disclosures related to a capital raising project (convertible bond issuance) and its associated business plans and market analysis. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a regulatory response document related to capital raising and listing approval. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (8600 characters) and detailed content support this classification with high confidence.
2024-05-15 Chinese
奥锐特药业股份有限公司2023年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2023 年年度股东大会会议资料" which translates to "2023 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda items for the 2023 AGM, including proposals related to the 2023 Annual Report, Board of Directors work report, Supervisory Board work report, financial statements, profit distribution, auditor appointment, and remuneration plans. The document also includes meeting procedures, voting instructions, and other materials typically provided to shareholders for an AGM. It is not the annual report itself but the materials prepared for the AGM to discuss and approve various reports and proposals. The length (15,000 characters) and content confirm it is a comprehensive AGM information packet rather than a brief announcement or a transcript. Therefore, the document fits the category of AGM Information (AGM-R).
2024-05-13 Chinese
奥锐特药业股份有限公司关于为全资子公司提供担保进展情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of providing guarantees by the company for its wholly-owned subsidiary. It details the guarantee amount, the parties involved, the internal decision-making process, financial data of the subsidiary, and the board's opinions. There is no indication that this is a full financial report, audit report, or earnings release. It is a regulatory announcement about a specific financing-related guarantee event. The document length is 2398 characters, which is relatively short and focused on a specific guarantee update. This fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company.
2024-05-05 Chinese
奥锐特药业股份有限公司关于召开2023年度暨2024年第一季度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of an upcoming earnings explanation meeting (业绩说明会) for the 2023 annual and 2024 first quarter results. It mentions the date, time, location, and participation methods for the meeting, but does not contain any actual financial data or detailed financial analysis. The document also references that the 2023 annual report and 2024 first quarter report have already been published. Given the document's short length (1478 characters) and its nature as a meeting announcement rather than the report or transcript itself, it fits the category of an Investor Presentation announcement or Earnings Release meeting notice. However, since it is specifically about an earnings explanation meeting and not the earnings release itself, and it is an announcement of a meeting rather than the meeting transcript or presentation, the best fitting category is Investor Presentation (IP).
2024-04-28 Chinese
奥锐特药业股份有限公司第三届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of 奥锐特药业股份有限公司 regarding multiple agenda items including approval of the 2023 Annual Report, 2023 Supervisory Board Work Report, 2023 Financial Final Accounts, 2023 Profit Distribution Plan, 2023 Internal Control Evaluation Report, renewal of the 2024 audit firm, 2024 Supervisory Board remuneration plan, use of idle funds for entrusted wealth management, accounting policy changes, and the 2024 Q1 report. The document does not contain the full financial reports or detailed financial data itself but rather resolutions approving these reports and plans, with references to where the full reports are published (Shanghai Stock Exchange website and newspapers). The document length is 3238 characters, which is relatively short and mainly serves as an announcement of meeting resolutions and approvals. According to the "Menu vs Meal" rule, this is an announcement of approvals and resolutions, not the reports themselves. Therefore, the document is best classified as a Regulatory Filing (RNS) because it is a formal announcement of supervisory board meeting resolutions and approvals related to various reports and plans, without containing the full reports or detailed financial data.
2024-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.